Mental Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Schering-Plough Corporation
Companies announce license, collaboration agreement for assay technology
December 17th, 2005
Schering-Plough Corporation (SGP) and Oncomethylome Sciences, a privately held company, announced a collaboration and license agreement for Schering-Plough to utilize assay technology from Oncomethylome Sciences that measures the methylation status of the MGMT gene in patients with glioblastoma multiforme (GBM), a form of malignant brain cancer, treated with temodar (temozolomide). Under the collaboration, the DNA methylation status of the MGMT gene is being evaluated for its potential role in optimizing Temodar therapy in patients with GBM brain cancer. Under the terms of the agreement, Schering-Plough receives a worldwide, nonexclusive license from...
Source: Mental Health Law Weekly (2005-12-17)
|
